Intellia Therapeutics, INC

Intellia Therapeutics announced additional positive Phase 3 results for its hereditary angioedema treatment, lonvoguran ziclumeran (lonvo-z), showing significant reductions in monthly attacks and improved quality of life.

Intellia Therapeutics held its annual meeting on June 9, 2026, where shareholders elected directors, ratified auditor appointment, and approved executive compensation.

Intellia Therapeutics reported Q1 2026 results, highlighting positive Phase 3 data for lonvo-z in HAE, initiation of a rolling BLA submission, and resumption of ATTR trials, with cash runway extended into 2028.

Intellia Therapeutics has successfully completed a public offering of common stock, raising approximately $194.6 million in net proceeds to fund clinical development and operations.

Intellia Therapeutics announced positive topline results from its Phase 3 HAELO trial for lonvo-z in hereditary angioedema, meeting primary and secondary endpoints and initiating a rolling BLA submission.

Intellia Therapeutics, Inc. has amended its bylaws to allow shareholders to cure notice deficiencies and designate federal courts as the exclusive forum for securities-related lawsuits.

Intellia Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its CRISPR-based gene editing programs for HAE and ATTR amyloidosis, alongside a net loss of $96.2 million.

Intellia Therapeutics reports reduced net loss but faces a clinical hold on its lead ATTR amyloidosis program, nex-z, following a patient death.

Intellia Therapeutics reports a narrower net loss in Q2 2025, driven by strategic restructuring and strong clinical progress in its lead gene editing programs for ATTR amyloidosis and hereditary angioedema.

Intellia Therapeutics announces its Q1 2025 financial results, showcasing ongoing clinical advancements in its CRISPR-based therapies for ATTR amyloidosis and hereditary angioedema.

Intellia Therapeutics' third quarter 2024 report highlights progress in clinical trials and financial updates, including a net loss of $135.7 million.

Intellia Therapeutics' second quarter 2024 results show a net loss, increased R&D spending, and progress in clinical trials for gene editing therapies.

Intellia Therapeutics' 2025 annual report highlights significant progress for its HAE program with anticipated 2027 launch, while its ATTR program faces a clinical hold and substantial net losses continue.

Intellia Therapeutics highlights progress in CRISPR-based therapies for ATTR amyloidosis and HAE while reporting its 2024 financial results.

Intellia Therapeutics, a clinical-stage gene editing company, released its 2023 financial results and provided an update on its business operations, highlighting progress in its CRISPR/Cas9-based therapeutic programs.

Edward J Dulac Iii, EVP, Chief Financial Officer of Intellia Therapeutics, Inc., sold 8,111 shares of common stock on July 22, 2026 for $11.25 per share.

Michael P. Dube, VP and Chief Accounting Officer of Intellia Therapeutics, reported a transaction involving the sale of 2,641 shares of common stock to cover tax obligations upon the vesting of RSUs.

Intellia Therapeutics EVP and CFO Edward J III Dulac sold 4,677 shares of common stock for $18 per share under a pre-arranged 10b5-1 trading plan.

Director Frank Verwiel was granted 9,200 restricted stock units and 13,300 stock options by Intellia Therapeutics.

Intellia Therapeutics director Georgia Keresty was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Intellia Therapeutics director Jesse Goodman was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Intellia Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and preparations for the 2027 commercial launch of its lead product candidate.

Intellia Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on director elections, auditor ratification, executive compensation, and a new equity incentive plan.

Intellia Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, outlining proposals for director elections, auditor ratification, executive compensation, and a new equity incentive plan.

Intellia Therapeutics will hold its annual stockholder meeting virtually on June 12, 2024, featuring proposals including the election of directors, ratification of auditors, executive compensation approval, and an amendment to limit officer liability.

Intellia Therapeutics will hold its 2024 Annual Meeting of Stockholders online on June 12, 2024, to vote on director elections, auditor ratification, executive compensation, and an amendment to limit officer liability.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Intellia Therapeutics Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.3% of Intellia Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G for Intellia Therapeutics Inc., reporting 0% beneficial ownership following an internal realignment.

The Goldman Sachs Group and its subsidiary report a 2.7% passive beneficial ownership in Intellia Therapeutics, Inc. as of December 31, 2025.

Contrarius Investment Management entities have reported a 0.6% beneficial ownership stake in Intellia Therapeutics, Inc. as of December 31, 2025.

State Street Corporation has reported a 5.5% beneficial ownership stake in Intellia Therapeutics Inc., holding over 6.4 million common shares.